Optain Health Secures $26M Series A for Global AI-Powered Retinal Screening Expansion
September 11, 2025, 9:36 pm
Location: United States, Ohio, Columbus
Employees: 10001+
Founded date: 1834
Location: United States, Texas, Houston
Employees: 10001+
Founded date: 1907
Total raised: $5M
Optain Health secures $26 million in Series A funding. Insight Partners leads the round. Seven major U.S. health systems invest. This capital fuels global expansion of Optain's AI-powered robotic retinal imaging platform. It brings advanced oculomics into primary care. The technology detects critical eye diseases and assesses systemic health risks. It promises earlier diagnosis, wider access to care, and improved patient outcomes. A new era for preventive health is here.
Optain Health recently secured $26 million. This Series A funding round was oversubscribed. Global software investor Insight Partners led the investment. This capital fuels significant expansion for the healthcare technology firm.
Optain pioneers oculomics. This innovative science uses the eye as a window into whole-body health. Its platform features advanced robotic retinal imaging. A portable camera captures images rapidly. Pupil dilation is unnecessary. Integrated AI workflows analyze the data.
The system detects critical eye diseases. Diabetic retinopathy, glaucoma, and age-related macular degeneration are primary targets. It also assesses cardiovascular disease risk. This offers comprehensive health insights from one non-invasive test. Early detection improves patient prognosis.
Optain aims to democratize disease screening. The technology expands oculomics access. It reaches primary care, optometry, and other non-specialist settings. Minimal specialist staffing is required. Workflow disruption remains low. This integration simplifies preventive health measures.
In the U.S., Optain delivers rapid teleophthalmology grading. This screens for diabetic retinopathy and other conditions. It closes critical care gaps. It provides timely diagnoses. This service enhances healthcare accessibility.
The $26 million investment enables enterprise deployments. It opens new markets globally. It also pushes the frontier of retinal revelations. Optain’s core mission is faster, easier, more equitable disease screening. This funding accelerates that vision.
Insight Partners leads a strong consortium of investors. Seven major U.S. health systems participate. These include Memorial Hermann Health System, Northwell Health, Novant Health, The Ohio State University Wexner Medical Center, and UPMC. These systems collectively serve 28 million patients across 25 states.
These strategic health systems will deploy Optain's platform. They will integrate it across their vast networks. This expands screening access for millions. It aims to close critical care gaps. Patient outcomes will see substantial improvement.
Additional investors further extend Optain’s reach. Informed Ventures, Lumio Capital, Meridian Ventures, and the UniQuest Extension Fund are involved. They will accelerate Optain's global footprint. This expansion targets Australia, Europe, the Middle East, and Southeast Asia.
Optain Health emerged in 2023. Aegis Ventures co-created the company. The Aegis Digital Consortium also provides strong backing. This consortium unites eleven leading regional U.S. health systems. They collaborate to co-develop AI-driven health tech solutions.
Clinical leaders strongly endorse Optain’s approach. They recognize early retinal screening’s power. It addresses critical care gaps in chronic disease management. The solution meets patients where they are. This facilitates real adoption within clinical settings. It enables early detection. It drives better patient outcomes.
Optain's technology builds on robust research. It stems from over a decade of Australian R&D. Professor Mingguang He led this foundational work. Optain now makes significant new investments in Australian R&D. Local teams will spearhead global expansion outside the U.S. This highlights a commitment to ongoing innovation.
Exporting Australian AI innovation remains a priority. This improves equitable access to healthcare worldwide. It enhances patient outcomes globally. Optain Health proudly leads this vital mission. It leverages its Australian roots for global impact.
Optain transforms preventive health. Its AI-enabled software and hardware are central to this transformation. They deliver real-time, non-invasive detection capabilities. Eye and systemic conditions are precisely targeted. This shifts healthcare towards proactive models.
The portable robotic retinal camera, AI, and teleophthalmology service empower clinicians. It offers an affordable point-of-care tool. This tool effectively closes care gaps. It reduces avoidable costs for health systems. Most importantly, it significantly improves patient outcomes.
This substantial funding marks a pivotal moment for Optain. It accelerates a paradigm shift in healthcare. Preventive health will see significant advancements. AI and oculomics are poised to redefine early disease detection strategies. The future of health screening is here. It is accessible. It is intelligent. It is global.
Optain Health recently secured $26 million. This Series A funding round was oversubscribed. Global software investor Insight Partners led the investment. This capital fuels significant expansion for the healthcare technology firm.
Optain pioneers oculomics. This innovative science uses the eye as a window into whole-body health. Its platform features advanced robotic retinal imaging. A portable camera captures images rapidly. Pupil dilation is unnecessary. Integrated AI workflows analyze the data.
The system detects critical eye diseases. Diabetic retinopathy, glaucoma, and age-related macular degeneration are primary targets. It also assesses cardiovascular disease risk. This offers comprehensive health insights from one non-invasive test. Early detection improves patient prognosis.
Optain aims to democratize disease screening. The technology expands oculomics access. It reaches primary care, optometry, and other non-specialist settings. Minimal specialist staffing is required. Workflow disruption remains low. This integration simplifies preventive health measures.
In the U.S., Optain delivers rapid teleophthalmology grading. This screens for diabetic retinopathy and other conditions. It closes critical care gaps. It provides timely diagnoses. This service enhances healthcare accessibility.
The $26 million investment enables enterprise deployments. It opens new markets globally. It also pushes the frontier of retinal revelations. Optain’s core mission is faster, easier, more equitable disease screening. This funding accelerates that vision.
Insight Partners leads a strong consortium of investors. Seven major U.S. health systems participate. These include Memorial Hermann Health System, Northwell Health, Novant Health, The Ohio State University Wexner Medical Center, and UPMC. These systems collectively serve 28 million patients across 25 states.
These strategic health systems will deploy Optain's platform. They will integrate it across their vast networks. This expands screening access for millions. It aims to close critical care gaps. Patient outcomes will see substantial improvement.
Additional investors further extend Optain’s reach. Informed Ventures, Lumio Capital, Meridian Ventures, and the UniQuest Extension Fund are involved. They will accelerate Optain's global footprint. This expansion targets Australia, Europe, the Middle East, and Southeast Asia.
Optain Health emerged in 2023. Aegis Ventures co-created the company. The Aegis Digital Consortium also provides strong backing. This consortium unites eleven leading regional U.S. health systems. They collaborate to co-develop AI-driven health tech solutions.
Clinical leaders strongly endorse Optain’s approach. They recognize early retinal screening’s power. It addresses critical care gaps in chronic disease management. The solution meets patients where they are. This facilitates real adoption within clinical settings. It enables early detection. It drives better patient outcomes.
Optain's technology builds on robust research. It stems from over a decade of Australian R&D. Professor Mingguang He led this foundational work. Optain now makes significant new investments in Australian R&D. Local teams will spearhead global expansion outside the U.S. This highlights a commitment to ongoing innovation.
Exporting Australian AI innovation remains a priority. This improves equitable access to healthcare worldwide. It enhances patient outcomes globally. Optain Health proudly leads this vital mission. It leverages its Australian roots for global impact.
Optain transforms preventive health. Its AI-enabled software and hardware are central to this transformation. They deliver real-time, non-invasive detection capabilities. Eye and systemic conditions are precisely targeted. This shifts healthcare towards proactive models.
The portable robotic retinal camera, AI, and teleophthalmology service empower clinicians. It offers an affordable point-of-care tool. This tool effectively closes care gaps. It reduces avoidable costs for health systems. Most importantly, it significantly improves patient outcomes.
This substantial funding marks a pivotal moment for Optain. It accelerates a paradigm shift in healthcare. Preventive health will see significant advancements. AI and oculomics are poised to redefine early disease detection strategies. The future of health screening is here. It is accessible. It is intelligent. It is global.